{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:33:40Z","timestamp":1788554020530,"version":"build-2803163510"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005339","name":"American Academy of Neurology","doi-asserted-by":"publisher","award":["Clinical Research Training Scholarship"],"award-info":[{"award-number":["Clinical Research Training Scholarship"]}],"id":[{"id":"10.13039\/100005339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11910-025-01429-3","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T07:40:39Z","timestamp":1750405239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recent Advances in Diagnosis, Management, Treatment, and Prevention of Neuropathies in Cancer Patients"],"prefix":"10.1007","volume":"25","author":[{"given":"John Y.","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Paulino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Finnemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Tentor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"1429_CR1","doi-asserted-by":"crossref","unstructured":"D\u2019Souza RS, Saini C, Hussain N, Javed S, Prokop L, Her YF. Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis of data from 28 countries, 2000-24. Reg Anesth Pain Med. 2025;rapm-2024-106229.","DOI":"10.1136\/rapm-2024-106229"},{"issue":"11","key":"1429_CR2","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.3390\/ijerph18115677","volume":"18","author":"HW Hung","year":"2021","unstructured":"Hung HW, Liu CY, Chen HF, Chang CC, Chen SC. Impact of chemotherapy-Induced peripheral neuropathy on quality of life in patients with advanced lung Cancer receiving Platinum-Based chemotherapy. Int J Environ Res Public Health. 2021;18(11):5677.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"1429_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11764-020-00923-6","volume":"15","author":"CS Bonhof","year":"2021","unstructured":"Bonhof CS, van de Poll-Franse LV, Wasowicz DK, Beerepoot LV, Vreugdenhil G, Mols F. The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients. J Cancer Surviv. 2021;15(2):190\u2013200.","journal-title":"J Cancer Surviv"},{"issue":"33","key":"1429_CR4","doi-asserted-by":"publisher","first-page":"e21695","DOI":"10.1097\/MD.0000000000021695","volume":"99","author":"B Prieto-Callejero","year":"2020","unstructured":"Prieto-Callejero B, Rivera F, Fagundo-Rivera J, Romero A, Romero-Mart\u00edn M, G\u00f3mez-Salgado J, et al. Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Med (Baltim). 2020;99(33):e21695.","journal-title":"Med (Baltim)"},{"key":"1429_CR5","doi-asserted-by":"publisher","first-page":"1345811","DOI":"10.3389\/fnmol.2024.1345811","volume":"17","author":"X Chen","year":"2024","unstructured":"Chen X, Gan Y, Au NPB, Ma CHE. Current Understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2024;17:1345811.","journal-title":"Front Mol Neurosci"},{"issue":"13","key":"1429_CR6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EML Smith","year":"2013","unstructured":"Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of Duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359\u201367.","journal-title":"JAMA"},{"issue":"3","key":"1429_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10549-022-06670-9","volume":"195","author":"K Engvall","year":"2022","unstructured":"Engvall K, Gr\u00e9en H, Fredrikson M, Lagerlund M, Lewin F, \u00c5vall-Lundqvist E. Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study. Breast Cancer Res Treat. 2022;195(3):379\u201391.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1429_CR8","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1007\/s11764-023-01402-4","volume":"18","author":"DL van de Graaf","year":"2024","unstructured":"van de Graaf DL, Engelen V, de Boer A, Vreugdenhil G, Smeets T, van der Lee ML, et al. Experiences of cancer survivors with chemotherapy-induced peripheral neuropathy in the netherlands: symptoms, daily limitations, involvement of healthcare professionals, and social support. J Cancer Surviv. 2024;18(5):1630\u20139.","journal-title":"J Cancer Surviv"},{"key":"1429_CR9","doi-asserted-by":"publisher","first-page":"153473542311851","DOI":"10.1177\/15347354231185110","volume":"22","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Morishita S, Nakano J, Okayama T, Inoue J, Tanaka T, et al. Neurological outcomes of Chemotherapy-Induced peripheral neuropathy in patients with cancer: A systematic review and Meta-Analysis. Integr Cancer Ther. 2023;22:15347354231185110.","journal-title":"Integr Cancer Ther"},{"issue":"5","key":"1429_CR10","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1200\/JOP.2012.000863","volume":"9","author":"RM Speck","year":"2013","unstructured":"Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, et al. Impact of Chemotherapy-Induced peripheral neuropathy on treatment delivery in nonmetastatic breast Cancer. JOP. 2013;9(5):e234\u201340.","journal-title":"JOP"},{"issue":"6","key":"1429_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/jnnp-2017-317215","volume":"89","author":"A Shah","year":"2018","unstructured":"Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018;89(6):636\u201341.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"1429_CR12","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1007\/s00520-012-1384-0","volume":"20","author":"LT Vahdat","year":"2012","unstructured":"Vahdat LT, Thomas ES, Roch\u00e9 HH, Hortobagyi GN, Sparano JA, Yelle L, et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer. 2012;20(11):2661\u20138.","journal-title":"Support Care Cancer"},{"key":"1429_CR13","doi-asserted-by":"publisher","first-page":"21386","DOI":"10.1038\/s41598-024-71977-0","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen Y, Ren X, Dai Y, Wang Y. Pharmacovigilance study of the association between peripheral neuropathy and antibody\u2013drug conjugates using the FDA adverse event reporting system. Sci Rep. 2024;14:21386.","journal-title":"Sci Rep"},{"issue":"11","key":"1429_CR14","doi-asserted-by":"publisher","first-page":"e2239788","DOI":"10.1001\/jamanetworkopen.2022.39788","volume":"5","author":"H Mo","year":"2022","unstructured":"Mo H, Yan X, Zhao F, Teng Y, Sun X, Lv Z, et al. Association of taxane type with Patient-Reported Chemotherapy-Induced peripheral neuropathy among patients with breast Cancer. JAMA Netw Open. 2022;5(11):e2239788.","journal-title":"JAMA Netw Open"},{"key":"1429_CR15","doi-asserted-by":"publisher","unstructured":"Lixian S, Xiaoqian Y, Luyan G, Lizhi Z, Rui D, Hongyue Y et al. Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study. Front Oncol [Internet]. 2024 Mar 7 [cited 2025 Apr 15];14. Available from: https:\/\/www.frontiersin.orghttps:\/\/www.frontiersin.org\/journals\/oncology\/articles\/https:\/\/doi.org\/10.3389\/fonc.2024.1327318\/full","DOI":"10.3389\/fonc.2024.1327318\/full"},{"issue":"2","key":"1429_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10549-021-06304-6","volume":"189","author":"IR Kleckner","year":"2021","unstructured":"Kleckner IR, Jusko TA, Culakova E, Chung K, Kleckner AS, Asare M, et al. Longitudinal study of inflammatory, behavioral, clinical and psychosocial risk factors for Chemotherapy-Induced peripheral neuropathy. Breast Cancer Res Treat. 2021;189(2):521\u201332.","journal-title":"Breast Cancer Res Treat"},{"key":"1429_CR17","doi-asserted-by":"publisher","unstructured":"Vargas-Aliaga A, De la Haba M, Contreras MJ, Morales Estevez C, Porras I, Cano MT et al. NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol [Internet]. 2024 Feb 26 [cited 2025 May 7];15. Available from: https:\/\/www.frontiersin.orghttps:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/https:\/\/doi.org\/10.3389\/fphar.2024.1352939\/full","DOI":"10.3389\/fphar.2024.1352939\/full"},{"issue":"3","key":"1429_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.radonc.2012.10.012","volume":"105","author":"S Delanian","year":"2012","unstructured":"Delanian S, Lefaix JL, Pradat PF. Radiation-induced neuropathy in cancer survivors. Radiother Oncol. 2012;105(3):273\u201382.","journal-title":"Radiother Oncol"},{"key":"1429_CR19","doi-asserted-by":"publisher","unstructured":"Skolka M, Shelly S, Pinto MV, Dubey D, Oishi T, Uhm JH et al. Clinical, Neurophysiologic, and Pathologic Features in Patients With Early-Onset Postradiation Neuropathy. Neurology [Internet]. 2023 Oct 3 [cited 2025 May 5];101(14). Available from: https:\/\/www.neurology.org\/doi\/https:\/\/doi.org\/10.1212\/WNL.0000000000207545","DOI":"10.1212\/WNL.0000000000207545"},{"issue":"4","key":"1429_CR20","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","volume":"8","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, Antoine JCG, Desestret V, Dubey D, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflammation. 2021;8(4):e1014.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"Pt 6","key":"1429_CR21","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","volume":"124","author":"F Graus","year":"2001","unstructured":"Graus F, Keime-Guibert F, Re\u00f1e R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(Pt 6):1138\u201348.","journal-title":"Brain"},{"issue":"17","key":"1429_CR22","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMra2023935","volume":"383","author":"AA Amato","year":"2020","unstructured":"Amato AA, Ropper AH. Sensory ganglionopathy. N Engl J Med. 2020;383(17):1657\u201362.","journal-title":"N Engl J Med"},{"issue":"1","key":"1429_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","volume":"23","author":"A Farina","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Vogrig A, Zekeridou A, Mu\u00f1iz-Castrillo S, Velasco R, et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol. 2024;23(1):81\u201394.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1429_CR24","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1212\/WNL.0000000000004803","volume":"90","author":"D Dubey","year":"2018","unstructured":"Dubey D, Lennon VA, Gadoth A, Pittock SJ, Flanagan EP, Schmeling JE, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018;90(2):e103\u201310.","journal-title":"Neurology"},{"issue":"20","key":"1429_CR25","doi-asserted-by":"publisher","first-page":"e1873","DOI":"10.1212\/WNL.0000000000008472","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D, Jitprapaikulsan J, Bi H, Do Campo RV, McKeon A, Pittock SJ, et al. Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome. Neurology. 2019;93(20):e1873\u201380.","journal-title":"Neurology"},{"issue":"4","key":"1429_CR26","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1212\/WNL.0000000000011218","volume":"96","author":"S Shah","year":"2021","unstructured":"Shah S, Vazquez Do Campo R, Kumar N, McKeon A, Flanagan EP, Klein C, et al. Paraneoplastic myeloneuropathies: clinical, oncologic, and serologic accompaniments. Neurology. 2021;96(4):e632\u20139.","journal-title":"Neurology"},{"issue":"3","key":"1429_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/jnnp-2019-322175","volume":"91","author":"J Jitprapaikulsan","year":"2020","unstructured":"Jitprapaikulsan J, Klein CJ, Pittock SJ, Gadoth A, McKeon A, Mills JR, et al. Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. J Neurol Neurosurg Psychiatry. 2020;91(3):328\u201330.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"16","key":"1429_CR28","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, et al. Neurologic adverse events of immune checkpoint inhibitors: A systematic review. Neurology. 2021;96(16):754\u201366.","journal-title":"Neurology"},{"issue":"6","key":"1429_CR29","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s00415-023-11625-1","volume":"270","author":"S Rossi","year":"2023","unstructured":"Rossi S, Gelsomino F, Rinaldi R, Muccioli L, Comito F, Di Federico A, et al. Peripheral nervous system adverse events associated with immune checkpoint inhibitors. J Neurol. 2023;270(6):2975\u201386.","journal-title":"J Neurol"},{"issue":"1","key":"1429_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunotherapy cancer. 2019;7(1):134.","journal-title":"J Immunotherapy cancer"},{"key":"1429_CR31","doi-asserted-by":"publisher","unstructured":"Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology [Internet]. 2019 Sep 10 [cited 2025 Apr 27];93(11). Available from: https:\/\/www.neurology.org\/doi\/https:\/\/doi.org\/10.1212\/WNL.0000000000008091","DOI":"10.1212\/WNL.0000000000008091"},{"key":"1429_CR32","doi-asserted-by":"crossref","unstructured":"Staff NP, Windebank AJ. Peripheral neuropathy due to vitamin deficiency, toxins, and medications: CONTINUUM: lifelong learning in neurology. 2014;20:1293\u2013306.","DOI":"10.1212\/01.CON.0000455880.06675.5a"},{"issue":"2","key":"1429_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ncl.2013.02.002","volume":"31","author":"N Hammond","year":"2013","unstructured":"Hammond N, Wang Y, Dimachkie MM, Barohn RJ. Nutritional neuropathies. Neurol Clin. 2013;31(2):477\u201389.","journal-title":"Neurol Clin"},{"key":"1429_CR34","doi-asserted-by":"publisher","first-page":"910770","DOI":"10.3389\/fonc.2022.910770","volume":"12","author":"P Bossi","year":"2022","unstructured":"Bossi P, De Luca R, Ciani O, D\u2019Angelo E, Caccialanza R. Malnutrition management in oncology: an expert view on controversial issues and future perspectives. Front Oncol. 2022;12:910770.","journal-title":"Front Oncol"},{"issue":"2","key":"1429_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00595-016-1341-5","volume":"47","author":"Y Rino","year":"2017","unstructured":"Rino Y, Oshima T, Yoshikawa T. Changes in fat-soluble vitamin levels after gastrectomy for gastric cancer. Surg Today. 2017;47(2):145\u201350.","journal-title":"Surg Today"},{"issue":"7","key":"1429_CR36","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00520-015-2725-6","volume":"23","author":"JM Schloss","year":"2015","unstructured":"Schloss JM, Colosimo M, Airey C, Vitetta L. Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency. Support Care Cancer. 2015;23(7):1843\u201350.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1429_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41583-020-0269-3","volume":"21","author":"MP Coleman","year":"2020","unstructured":"Coleman MP, H\u00f6ke A. Programmed axon degeneration: from mouse to mechanism to medicine. Nat Rev Neurosci. 2020;21(4):183\u201396.","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"1429_CR38","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.neuron.2021.02.009","volume":"109","author":"MD Figley","year":"2021","unstructured":"Figley MD, Gu W, Nanson JD, Shi Y, Sasaki Y, Cunnea K, et al. SARM1 is a metabolic sensor activated by an increased NMN\/NAD\u2009+\u2009ratio to trigger axon degeneration. Neuron. 2021;109(7):1118\u2013e113611.","journal-title":"Neuron"},{"issue":"11","key":"1429_CR39","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/jnnp-2021-328323","volume":"94","author":"SB Park","year":"2023","unstructured":"Park SB, Cetinkaya-Fisgin A, Argyriou AA, H\u00f6ke A, Cavaletti G, Alberti P. Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence. J Neurol Neurosurg Psychiatry. 2023;94(11):962\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"16","key":"1429_CR40","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3390\/cells11162499","volume":"11","author":"P Alberti","year":"2022","unstructured":"Alberti P, Semperboni S, Cavaletti G, Scuteri A, Neurons. The interplay between cytoskeleton, ion channels\/transporters and mitochondria. Cells. 2022;11(16):2499.","journal-title":"Cells"},{"issue":"1","key":"1429_CR41","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1038\/s41598-020-60990-8","volume":"10","author":"AM Cirrincione","year":"2020","unstructured":"Cirrincione AM, Pellegrini AD, Dominy JR, Benjamin ME, Utkina-Sosunova I, Lotti F, et al. Paclitaxel-induced peripheral neuropathy is caused by epidermal ROS and mitochondrial damage through conserved MMP-13 activation. Sci Rep. 2020;10(1):3970.","journal-title":"Sci Rep"},{"key":"1429_CR42","doi-asserted-by":"publisher","first-page":"122219","DOI":"10.1016\/j.lfs.2023.122219","volume":"334","author":"B Albin","year":"2023","unstructured":"Albin B, Qubbaj K, Tiwari AP, Adhikari P, Yang IH. Mitochondrial trafficking as a protective mechanism against chemotherapy drug-induced peripheral neuropathy: identifying the key site of action. Life Sci. 2023;334:122219.","journal-title":"Life Sci"},{"key":"1429_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.expneurol.2016.11.015","volume":"288","author":"EL Gornstein","year":"2017","unstructured":"Gornstein EL, Schwarz TL. Neurotoxic mechanisms of Paclitaxel are local to the distal axon and independent of transport defects. Exp Neurol. 2017;288:153\u201366.","journal-title":"Exp Neurol"},{"issue":"3","key":"1429_CR44","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.nbd.2010.11.017","volume":"41","author":"JL Podratz","year":"2011","unstructured":"Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis. 2011;41(3):661\u20138.","journal-title":"Neurobiol Dis"},{"key":"1429_CR45","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1186\/1744-8069-4-10","volume":"4","author":"JM Jimenez-Andrade","year":"2008","unstructured":"Jimenez-Andrade JM, Herrera MB, Ghilardi JR, Vardanyan M, Melemedjian OK, Mantyh PW. Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for Chemical-Induced peripheral sensory neuropathies. Mol Pain. 2008;4:1744\u20138069.","journal-title":"Mol Pain"},{"issue":"4","key":"1429_CR46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5306\/wjco.v8.i4.329","volume":"8","author":"O Kanat","year":"2017","unstructured":"Kanat O, Ertas H, Caner B. Platinum-induced neurotoxicity: A review of possible mechanisms. WJCO. 2017;8(4):329.","journal-title":"WJCO"},{"issue":"4","key":"1429_CR47","doi-asserted-by":"publisher","first-page":"e2012685118","DOI":"10.1073\/pnas.2012685118","volume":"118","author":"ME Pero","year":"2021","unstructured":"Pero ME, Meregalli C, Qu X, Shin GJ, eun, Kumar A, Shorey M, et al. Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy. Proc Natl Acad Sci USA. 2021;118(4):e2012685118.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"1429_CR48","doi-asserted-by":"publisher","first-page":"dmm049358","DOI":"10.1242\/dmm.049358","volume":"15","author":"AR Snavely","year":"2022","unstructured":"Snavely AR, Heo K, Petrova V, Ho TSY, Huang X, Hermawan C, et al. Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion. Dis Models Mech. 2022;15(12):dmm049358.","journal-title":"Dis Models Mech"},{"issue":"17","key":"1429_CR49","doi-asserted-by":"publisher","first-page":"e129920","DOI":"10.1172\/jci.insight.129920","volume":"4","author":"S Geisler","year":"2019","unstructured":"Geisler S, Doan RA, Cheng GC, Cetinkaya-Fisgin A, Huang SX, H\u00f6ke A, et al. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program. JCI Insight. 2019;4(17):e129920.","journal-title":"JCI Insight"},{"key":"1429_CR50","doi-asserted-by":"publisher","first-page":"116070","DOI":"10.1016\/j.bcp.2024.116070","volume":"222","author":"J Ollodart","year":"2024","unstructured":"Ollodart J, Steele LR, Romero-Sandoval EA, Strowd RE, Shiozawa Y. Contributions of neuroimmune interactions to chemotherapy-induced peripheral neuropathy development and its prevention\/therapy. Biochem Pharmacol. 2024;222:116070.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"1429_CR51","doi-asserted-by":"publisher","first-page":"109940","DOI":"10.1016\/j.isci.2024.109940","volume":"27","author":"R Sugisawa","year":"2024","unstructured":"Sugisawa R, Shanahan KA, Davis GM, Davey GP, Bowie AG. SARM1 regulates pro-inflammatory cytokine expression in human monocytes by NADase-dependent and -independent mechanisms. iScience. 2024;27(6):109940.","journal-title":"iScience"},{"issue":"6","key":"1429_CR52","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1136\/jnnp-2023-332454","volume":"95","author":"LF O\u2019Donnell","year":"2024","unstructured":"O\u2019Donnell LF, Pipis M, Thornton JS, Kanber B, Wastling S, McDowell A, et al. Quantitative MRI outcome measures in CMT1A using automated lower limb muscle segmentation. J Neurol Neurosurg Psychiatry. 2024;95(6):500\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1429_CR53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/mus.28306","volume":"71","author":"F Diaz","year":"2025","unstructured":"Diaz F, Thornton JS, Wastling SS, Asaab A, Morrow JM, Zafeiropoulos N, et al. Longitudinal quantitative MRI provides responsive outcome measures for early and late muscle changes in ALS. Muscle Nerve. 2025;71(2):171\u201382.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1429_CR54","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/mus.27647","volume":"66","author":"B Sveinsson","year":"2022","unstructured":"Sveinsson B, Rowe OE, Stockmann JP, Park DJ, Lally PJ, Rosen MS, et al. Feasibility of simultaneous high-resolution anatomical and quantitative magnetic resonance imaging of sciatic nerves in patients with Charcot\u2013Marie\u2013Tooth type 1A (CMT1A) at 7T. Muscle Nerve. 2022;66(2):206\u201311.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1429_CR55","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10549-020-05897-8","volume":"184","author":"P Chalasani","year":"2020","unstructured":"Chalasani P, Taljanovic M, Segar J, Farr K, Win H, Wertheim BC, et al. Diffuse tensor imaging of lower extremities: a novel MR imaging technique for chemotherapy-induced peripheral neuropathy. Breast Cancer Res Treat. 2020;184(3):771\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1429_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mus.26833","volume":"61","author":"TW Lycan","year":"2020","unstructured":"Lycan TW, Hsu F, Ahn CS, Thomas A, Walker FO, Sangueza OP, et al. Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer. Muscle Nerve. 2020;61(5):587\u201394.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1429_CR57","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/mus.28260","volume":"70","author":"L Pelosi","year":"2024","unstructured":"Pelosi L, Coraci D, Mulroy E, Leadbetter R, Padua L, Roxburgh R. Lower limb nerve ultrasound: A four-way comparison of acquired and inherited axonopathy, inherited neuronopathy and healthy controls. Muscle Nerve. 2024;70(6):1263\u20137.","journal-title":"Muscle Nerve"},{"issue":"5","key":"1429_CR58","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/mus.28078","volume":"69","author":"JB Meiling","year":"2024","unstructured":"Meiling JB, Andrapalliyal N, McGhee MB, Penry VB, Cartwright MS, Gandhi Mehta RK. Ultrahigh-frequency ultrasound of fascicles in the common fibular, superficial fibular, and Sural nerves. Muscle Nerve. 2024;69(5):631\u20136.","journal-title":"Muscle Nerve"},{"key":"1429_CR59","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.clinph.2024.08.011","volume":"166","author":"T Hayashi","year":"2024","unstructured":"Hayashi T, Matsumoto N, Hatake S, Takeshi Y, Suzuki K, Nishiyama Y, et al. Nerve sonography to detect intraneural microvascularity in patients with peripheral neuropathy. Clin Neurophysiol. 2024;166:244\u20139.","journal-title":"Clin Neurophysiol"},{"issue":"1166","key":"1429_CR60","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/bjr\/tqae227","volume":"98","author":"S Zheng","year":"2025","unstructured":"Zheng S, Zhu M, Fan G, Yang X, Bai M. Application value of strain elastography and shear wave elastography in patients with type 2 diabetic peripheral neuropathy: a prospective observational study. Br J Radiol. 2025;98(1166):280\u20136.","journal-title":"Br J Radiol"},{"issue":"1","key":"1429_CR61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s40478-023-01685-9","volume":"11","author":"S Hartinger","year":"2023","unstructured":"Hartinger S, Hammersen J, Leistner NA, Lawson McLean A, Risse C, Senft C, et al. The role of neuromuscular ultrasound in diagnostics of peripheral neuropathies induced by cytostatic agents or immunotherapies. Acta Neuropathol Commun. 2023;11(1):187.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"1429_CR62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ejrnm.2018.03.002","volume":"49","author":"MF Sherif","year":"2018","unstructured":"Sherif MF, Dawoud MM, Nagy HA, Ghannam AA. Diagnostic accuracy of 18-F FDG-PET\/CT in evaluation of malignant neuronal involvement in neurologically manifested cancer patients. Egypt J Radiol Nuclear Med. 2018;49(2):453\u201360.","journal-title":"Egypt J Radiol Nuclear Med"},{"issue":"1","key":"1429_CR63","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1148\/radiol.2019190861","volume":"293","author":"KS Ng","year":"2019","unstructured":"Ng KS, Leung JMS. Vincristine-induced polyneuropathy at FDG PET\/CT. Radiology. 2019;293(1):36\u201336.","journal-title":"Radiology"},{"issue":"8","key":"1429_CR64","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1429_CR65","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jns.12493","volume":"27","author":"S Karteri","year":"2022","unstructured":"Karteri S, Bruna J, Argyriou AA, Mariotto S, Velasco R, Alemany M, et al. Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. J Peripheral Nerv Sys. 2022;27(2):166\u201374.","journal-title":"J Peripheral Nerv Sys"},{"issue":"9","key":"1429_CR66","doi-asserted-by":"publisher","first-page":"e16369","DOI":"10.1111\/ene.16369","volume":"31","author":"R Velasco","year":"2024","unstructured":"Velasco R, Marco C, Domingo-Domenech E, Stradella A, Santos C, Laquente B, et al. Plasma neurofilament light chain levels in chemotherapy\u2010induced peripheral neurotoxicity according to type of anticancer drug. Euro J Neurol. 2024;31(9):e16369.","journal-title":"Euro J Neurol"},{"key":"1429_CR67","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2340\/1651-226X.2024.39895","volume":"63","author":"J Adra","year":"2024","unstructured":"Adra J, Giglio D, Karlsson P, Zetterberg H, Einbeigi Z. Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy. AO. 2024;63:636\u201341.","journal-title":"AO"},{"key":"1429_CR68","doi-asserted-by":"crossref","unstructured":"Trecarichi A, Duggett NA, Granat L, Lo S, Malik AN, Zuliani-\u00c1lvarez L et al. Preclinical evidence for mitochondrial DNA as a potential blood biomarker for chemotherapy-induced peripheral neuropathy. Taylor B, editor. PLoS ONE. 2022;17(1):e0262544.","DOI":"10.1371\/journal.pone.0262544"},{"issue":"11","key":"1429_CR69","doi-asserted-by":"publisher","first-page":"2400164","DOI":"10.1002\/jssc.202400164","volume":"47","author":"Y Hua","year":"2024","unstructured":"Hua Y, Wang R, Liu Y, Liu Q, Qi X, Ding Y, et al. Metabolomics analysis reveals characteristic metabolites in different levels of oxaliplatin-induced neurotoxicity. J Sep Sci. 2024;47(11):2400164.","journal-title":"J Sep Sci"},{"issue":"3","key":"1429_CR70","first-page":"30","volume":"24","author":"A Geronimo","year":"2025","unstructured":"Geronimo A, Johnson SA. Digital biomarkers in neuromuscular disease: recent advances. Practical Neurol (US). 2025;24(3):30\u20132.","journal-title":"Practical Neurol (US)"},{"issue":"1","key":"1429_CR71","doi-asserted-by":"publisher","first-page":"29681","DOI":"10.1038\/s41598-024-80177-9","volume":"14","author":"L Servais","year":"2024","unstructured":"Servais L, Strijbos P, Poleur M, Mirea A, Butoianu N, Sansone VA, et al. Evidentiary basis of the first regulatory qualification of a digital primary efficacy endpoint. Sci Rep. 2024;14(1):29681.","journal-title":"Sci Rep"},{"issue":"6","key":"1429_CR72","doi-asserted-by":"publisher","first-page":"pkac075","DOI":"10.1093\/jncics\/pkac075","volume":"6","author":"P Pfeiffer","year":"2022","unstructured":"Pfeiffer P, Lustberg M, N\u00e4sstr\u00f6m J, Carlsson S, Persson A, Nagahama F, et al. Calmangafodipir for prevention of Oxaliplatin-Induced peripheral neuropathy: two Placebo-Controlled, randomized phase 3 studies (POLAR-A\/POLAR-M). JNCI Cancer Spectr. 2022;6(6):pkac075.","journal-title":"JNCI Cancer Spectr"},{"issue":"12","key":"1429_CR73","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3390\/antiox10121937","volume":"10","author":"JOG Karlsson","year":"2021","unstructured":"Karlsson JOG, Jynge P, Ignarro LJ. The damaging outcome of the POLAR phase III trials was due to avoidable Time-Dependent redox interaction between oxaliplatin and pledox. Antioxid (Basel). 2021;10(12):1937.","journal-title":"Antioxid (Basel)"},{"key":"1429_CR74","unstructured":"Belayneh M. Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy (METACIN): a Randomized Double-blind Controlled Trial [Internet]. clinicaltrials.gov; 2025 Mar [cited 2025 Apr 25]. Report No.: NCT05786599. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05786599"},{"key":"1429_CR75","unstructured":"Institut Cancerologie de l\u2019Ouest. Capsaicin 179\u00a0mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy: a Phase 3 Randomized Multicentric Open-label Study. [Internet]. clinicaltrials.gov; 2024 Aug [cited 2025 Apr 25]. Report No.: NCT05840562. https:\/\/clinicaltrials.gov\/study\/NCT05840562."},{"issue":"28","key":"1429_CR76","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of Chemotherapy-Induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. JCO. 2020;38(28):3325\u201348.","journal-title":"JCO"},{"key":"1429_CR77","doi-asserted-by":"publisher","unstructured":"Michel LL, Schwarz D, Romar P, Feisst M, Hamberger D, Priester A et al. Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy: The POLAR Randomized Clinical Trial. JAMA Oncology [Internet]. 2025 Mar 6 [cited 2025 Apr 15]; Available from: https:\/\/doi.org\/10.1001\/jamaoncol.2025.0001","DOI":"10.1001\/jamaoncol.2025.0001"},{"issue":"4","key":"1429_CR78","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s00520-025-09378-w","volume":"33","author":"S Grenouillet","year":"2025","unstructured":"Grenouillet S, Balayssac D, Moisset X, Peyron R, Fauchon C. Analgesic efficacy of non-invasive neuromodulation techniques in chronic cancer pain: a systematic review. Support Care Cancer. 2025;33(4):346.","journal-title":"Support Care Cancer"},{"issue":"2","key":"1429_CR79","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neurom.2024.10.006","volume":"28","author":"PD Vu","year":"2025","unstructured":"Vu PD, Mach S, Javed S. Neurostimulation for the treatment of Cancer-Induced pain: A scoping review. Neuromodulation. 2025;28(2):191\u2013203.","journal-title":"Neuromodulation"},{"key":"1429_CR80","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.2147\/JPR.S315585","volume":"14","author":"MM Aman","year":"2021","unstructured":"Aman MM, Mahmoud A, Deer T, Sayed D, Hagedorn JM, Brogan SE, et al. The American society of pain and neuroscience (ASPN) best practices and guidelines for the interventional management of Cancer-Associated pain. J Pain Res. 2021;14:2139\u201364.","journal-title":"J Pain Res"},{"key":"1429_CR81","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12883-023-03485-z","volume":"23","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wang A, Wang M, Li G, Wei Q. Non-pharmacological therapy for chemotherapy-induced peripheral neurotoxicity: a network meta-analysis of randomized controlled trials. BMC Neurol. 2023;23:433.","journal-title":"BMC Neurol"},{"issue":"12","key":"1429_CR82","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3390\/nu14122403","volume":"14","author":"M Crichton","year":"2022","unstructured":"Crichton M, Yates PM, Agbejule OA, Spooner A, Chan RJ, Hart NH. Non-Pharmacological Self-Management strategies for Chemotherapy-Induced peripheral neuropathy in people with advanced cancer: A systematic review and Meta-Analysis. Nutrients. 2022;14(12):2403.","journal-title":"Nutrients"},{"issue":"10","key":"1429_CR83","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1007\/s00520-019-04680-w","volume":"27","author":"JM McCrary","year":"2019","unstructured":"McCrary JM, Goldstein D, Sandler CX, Barry BK, Marthick M, Timmins HC, et al. Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2019;27(10):3849\u201357.","journal-title":"Support Care Cancer"},{"key":"1429_CR84","doi-asserted-by":"publisher","first-page":"153473541983650","DOI":"10.1177\/1534735419836501","volume":"18","author":"A Molassiotis","year":"2019","unstructured":"Molassiotis A, Suen LKP, Cheng HL, Mok TSK, Lee SCY, Wang CH, et al. A randomized assessor-Blinded Wait-List-Controlled trial to assess the effectiveness of acupuncture in the management of Chemotherapy-Induced peripheral neuropathy. Integr Cancer Ther. 2019;18:1534735419836501.","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"1429_CR85","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-016-3759-2","volume":"156","author":"H Greenlee","year":"2016","unstructured":"Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, et al. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res Treat. 2016;156(3):453\u201364.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1429_CR86","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00520-019-04881-3","volume":"28","author":"C Loprinzi","year":"2020","unstructured":"Loprinzi C, Le-Rademacher JG, Majithia N, McMurray RP, O\u2019Neill CR, Bendel MA, et al. Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. Support Care Cancer. 2020;28(3):1183\u201397.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1429_CR87","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/0825859719827589","volume":"35","author":"TJ Smith","year":"2020","unstructured":"Smith TJ, Razzak AR, Blackford AL, Ensminger J, Saiki C, Longo-Schoberlein D, et al. A pilot randomized Sham-Controlled trial of MC5-A scrambler therapy in the treatment of chronic Chemotherapy-Induced peripheral neuropathy (CIPN). J Palliat Care. 2020;35(1):53\u20138.","journal-title":"J Palliat Care"},{"issue":"4","key":"1429_CR88","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jpain.2017.11.009","volume":"19","author":"R Knoerl","year":"2018","unstructured":"Knoerl R, Smith EML, Barton DL, Williams DA, Holden JE, Krauss JC, et al. Self-Guided online cognitive behavioral strategies for Chemotherapy-Induced peripheral neuropathy: A multicenter, pilot, randomized, Wait-List controlled trial. J Pain. 2018;19(4):382\u201394.","journal-title":"J Pain"},{"issue":"4","key":"1429_CR89","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.21037\/jgo-23-625","volume":"14","author":"M Wang","year":"2023","unstructured":"Wang M, Xu Y, Shi J, Zhuang C, Zhuang Y, Li J, et al. The effect of cognitive behavioral therapy on chemotherapy-induced side effects and immune function in colorectal cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial. J Gastrointest Oncol. 2023;14(4):1869\u201377.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"1429_CR90","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/s13063-022-06592-3","volume":"23","author":"DL van de Graaf","year":"2022","unstructured":"van de Graaf DL, Mols F, Trompetter HR, van der Lee ML, Schreurs KMG, B\u00f8r\u00f8sund E, et al. Effectiveness of the online acceptance and commitment therapy intervention embrace pain for cancer survivors with chronic painful chemotherapy-induced peripheral neuropathy: study protocol for a randomized controlled trial. Trials. 2022;23(1):642.","journal-title":"Trials"},{"issue":"2","key":"1429_CR91","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/tbj.13196","volume":"25","author":"M Aghili","year":"2019","unstructured":"Aghili M, Zare M, Mousavi N, Ghalehtaki R, Sotoudeh S, Kalaghchi B, et al. Efficacy of Gabapentin for the prevention of Paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial. Breast J. 2019;25(2):226\u201331.","journal-title":"Breast J"},{"issue":"3","key":"1429_CR92","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40261-019-00882-6","volume":"40","author":"E Salehifar","year":"2020","unstructured":"Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the efficacy and safety of Pregabalin and Duloxetine in Taxane-Induced sensory neuropathy: A randomized controlled trial. Clin Drug Investig. 2020;40(3):249\u201357.","journal-title":"Clin Drug Investig"},{"key":"1429_CR93","unstructured":"Commissioner O, of the FDA. FDA; 2025 [cited 2025 Apr 25]. FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain"},{"key":"1429_CR94","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2147\/JPR.S509144","volume":"18","author":"J McCoun","year":"2025","unstructured":"McCoun J, Winkle P, Solanki D, Urban J, Bertoch T, Oswald J, et al. Suzetrigine, a Non-Opioid NaV1.8 inhibitor with broad applicability for Moderate-to-Severe acute pain: A phase 3 Single-Arm study for surgical or Non-Surgical acute pain. J Pain Res. 2025;18:1569\u201376.","journal-title":"J Pain Res"},{"key":"1429_CR95","unstructured":"Vertex Pharmaceuticals Incorporated, Phase A. 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy [Internet]. clinicaltrials.gov; 2025 Apr [cited 2025 Apr 25]. Report No.: NCT06628908. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06628908"},{"issue":"3","key":"1429_CR96","first-page":"13","volume":"24","author":"B Kelly","year":"2025","unstructured":"Kelly B, Nawaz S, Gwathmey KG. Patient-reported outcome measures in neuromuscular disorders. Practical Neurol (US). 2025;24(3):13\u201320.","journal-title":"Practical Neurol (US)"},{"issue":"3","key":"1429_CR97","first-page":"21","volume":"24","author":"SP Uysal","year":"2025","unstructured":"Uysal SP, Sadjadi R. The minimal clinically important difference and its use in neuromuscular disorders. Practical Neurol (US). 2025;24(3):21\u20134.","journal-title":"Practical Neurol (US)"},{"key":"1429_CR98","unstructured":"Unity Health Toronto. Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN [Internet]. clinicaltrials.gov; 2025 Mar [cited 2025 May 20]. Report No.: NCT06731335. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06731335"},{"key":"1429_CR99","unstructured":"Antczak J. Analgesic Effect of Accelerated Repetitive Transcranial Magnetic Stimulation in Pain Related to Peripheral Neuropathy [Internet]. clinicaltrials.gov; 2024 Oct [cited 2025 May 20]. Report No.: NCT05295498. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05295498"},{"issue":"2","key":"1429_CR100","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/brainsci13020255","volume":"13","author":"S Akter","year":"2023","unstructured":"Akter S, Choubey M, Mohib MM, Arbee S, Sagor MAT, Mohiuddin MS. Stem cell therapy in diabetic polyneuropathy: recent advancements and future directions. Brain Sci. 2023;13(2):255.","journal-title":"Brain Sci"},{"key":"1429_CR101","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuroscience.2024.12.035","volume":"566","author":"SD Alizadeh","year":"2025","unstructured":"Alizadeh SD, Hassan Zadeh Tabatabaei MS, Rezaei Zadeh Rukerd M, Tabrizi R, Masoomi R, Banihashemian SZ, et al. The safety and efficacy of stem cell therapy for diabetic peripheral neuropathy in animal studies: A systematic review and meta-analysis. Neuroscience. 2025;566:49\u201359.","journal-title":"Neuroscience"},{"issue":"2","key":"1429_CR102","first-page":"1","volume":"6","author":"S Sharma","year":"2024","unstructured":"Sharma S, Rangarajan RV. Role of regenerative therapeutics in diabetic peripheral neuropathy: current advances and future prospects. Eur J Med Health Sci. 2024;6(2):1\u201310.","journal-title":"Eur J Med Health Sci"},{"issue":"3","key":"1429_CR103","doi-asserted-by":"publisher","first-page":"109052","DOI":"10.1016\/j.isci.2024.109052","volume":"27","author":"B Albin","year":"2024","unstructured":"Albin B, Adhikari P, Tiwari AP, Qubbaj K, Yang IH. Electrical stimulation enhances mitochondrial trafficking as a neuroprotective mechanism against chemotherapy-induced peripheral neuropathy. iScience. 2024;27(3):109052.","journal-title":"iScience"},{"issue":"20","key":"1429_CR104","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1111\/bph.16476","volume":"181","author":"S Im","year":"2024","unstructured":"Im S, Jeong DJ, Kim E, Choi J, Jang H, Kim YY, et al. A novel marine-derived mitophagy inducer ameliorates mitochondrial dysfunction and thermal hypersensitivity in paclitaxel\u2010induced peripheral neuropathy. Br J Pharmacol. 2024;181(20):4012\u201327.","journal-title":"Br J Pharmacol"},{"key":"1429_CR105","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/DDDT.S369111","volume":"16","author":"R Sun","year":"2022","unstructured":"Sun R, Liu J, Yu M, Xia M, Zhang Y, Sun X, et al. Paeoniflorin ameliorates BiPN by reducing IL6 levels and regulating PARKIN-Mediated mitochondrial autophagy. DDDT. 2022;16:2241\u201359.","journal-title":"DDDT"},{"key":"1429_CR106","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ygyno.2024.04.021","volume":"187","author":"M Zenatri","year":"2024","unstructured":"Zenatri M, Perennec T, Michon C, Gernier F, Grellard JM, Piloquet FX, et al. Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study. Gynecol Oncol. 2024;187:139\u201344.","journal-title":"Gynecol Oncol"},{"issue":"04","key":"1429_CR107","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4149\/BLL_2024_31","volume":"125","author":"B Mladosievicova","year":"2024","unstructured":"Mladosievicova B, Jablonicka MN, Tatayova L, Bernadic M. Genetic determinants of taxane-induced peripheral neuropathy. BLL. 2024;125(04):207\u201310.","journal-title":"BLL"},{"key":"1429_CR108","doi-asserted-by":"publisher","first-page":"864910","DOI":"10.3389\/fpain.2022.864910","volume":"3","author":"RL Rodwin","year":"2022","unstructured":"Rodwin RL, Siddiq NZ, Ehrlich BE, Lustberg MB. Biomarkers of Chemotherapy-Induced peripheral neuropathy: current status and future directions. Front Pain Res. 2022;3:864910.","journal-title":"Front Pain Res"},{"key":"1429_CR109","doi-asserted-by":"publisher","first-page":"e59505","DOI":"10.2196\/59505","volume":"26","author":"R AlSaad","year":"2024","unstructured":"AlSaad R, Abd-alrazaq A, Boughorbel S, Ahmed A, Renault MA, Damseh R, et al. Multimodal large Language models in health care: applications, challenges, and future outlook. J Med Internet Res. 2024;26:e59505.","journal-title":"J Med Internet Res"},{"key":"1429_CR110","doi-asserted-by":"publisher","first-page":"1474884","DOI":"10.3389\/fneur.2024.1474884","volume":"15","author":"M Garbey","year":"2024","unstructured":"Garbey M, Lesport Q, Girma H, \u00d6ztosun G, Abu-Rub M, Guidon AC, et al. Application of digital tools and artificial intelligence in the myasthenia Gravis core examination. Front Neurol. 2024;15:1474884.","journal-title":"Front Neurol"},{"key":"1429_CR111","doi-asserted-by":"crossref","unstructured":"Belayneh M, Hejazi S, Gagnon B, Hawley P. Methadone to treat chemotherapy-induced peripheral neuropathy (METACIN): study protocol. Pain Manag. 2025;1\u20139.","DOI":"10.1080\/17581869.2025.2494495"},{"issue":"1","key":"1429_CR112","first-page":"55","volume":"112","author":"Y Su","year":"2020","unstructured":"Su Y, Huang J, Wang S, Unger JM, Arias-Fuenzalida J, Shi Y, et al. The effects of Ganglioside-Monosialic acid in Taxane-Induced peripheral neurotoxicity in patients with breast cancer: A randomized trial. J Natl Cancer Inst. 2020;112(1):55\u201362.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1429_CR113","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpainsymman.2019.06.018","volume":"58","author":"XS Wang","year":"2019","unstructured":"Wang XS, Shi Q, Bhadkamkar NA, Cleeland CS, Garcia-Gonzalez A, Aguilar JR, et al. Minocycline for symptom reduction during Oxaliplatin-Based chemotherapy for colorectal cancer: A phase II randomized clinical trial. J Pain Symptom Manage. 2019;58(4):662\u201371.","journal-title":"J Pain Symptom Manage"},{"key":"1429_CR114","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.breast.2019.09.011","volume":"48","author":"KJ Ruddy","year":"2019","unstructured":"Ruddy KJ, Le-Rademacher J, Lacouture ME, Wilkinson M, Onitilo AA, Vander Woude AC, et al. Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial. Breast. 2019;48:89\u201397.","journal-title":"Breast"},{"issue":"4","key":"1429_CR115","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/NCC.0000000000000693","volume":"43","author":"S Dhawan","year":"2020","unstructured":"Dhawan S, Andrews R, Kumar L, Wadhwa S, Shukla G. A randomized controlled trial to assess the effectiveness of muscle strengthening and balancing exercises on Chemotherapy-Induced peripheral neuropathic pain and quality of life among Cancer patients. Cancer Nurs. 2020;43(4):269.","journal-title":"Cancer Nurs"},{"issue":"1","key":"1429_CR116","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12885-019-5522-7","volume":"19","author":"S Kneis","year":"2019","unstructured":"Kneis S, Wehrle A, M\u00fcller J, Maurer C, Ihorst G, Gollhofer A, et al. It\u2019s never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial. BMC Cancer. 2019;19(1):414.","journal-title":"BMC Cancer"},{"issue":"4","key":"1429_CR117","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1634\/theoncologist.2019-0489","volume":"25","author":"W Lu","year":"2020","unstructured":"Lu W, Giobbie-Hurder A, Freedman RA, Shin IH, Lin NU, Partridge AH, et al. Acupuncture for Chemotherapy\u2010Induced peripheral neuropathy in breast Cancer survivors: A randomized controlled pilot trial. Oncologist. 2020;25(4):310\u20138.","journal-title":"Oncologist"},{"key":"1429_CR118","unstructured":"VA Office of Research and Development. Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain [Internet]. clinicaltrials.gov; 2025 Mar [cited 2025 May 20]. Report No.: NCT05351801. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05351801"},{"key":"1429_CR119","unstructured":"Clavo B. Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ) [Internet]. clinicaltrials.gov; 2024 Mar [cited 2025 May 20]. Report No.: NCT04299893. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04299893"},{"key":"1429_CR120","unstructured":"Eli Lilly and Company, Phase A 2, Controlled RD-BP. Dose-Ranging Study to Evaluate LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain [Internet]. clinicaltrials.gov; 2025 Apr [cited 2025 May 20]. Report No.: NCT06074562. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06074562"},{"key":"1429_CR121","unstructured":"Biering-Soerensen B. Perineural Injections of Incobotulinumtoxin-A for Diabetic Neuropathic Pain of the Lower Extremities: A Double-blind, Randomized, Placebo-controlled Study [Internet]. clinicaltrials.gov; 2024 Apr [cited 2025 May 20]. Report No.: NCT05623111. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05623111"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01429-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-025-01429-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01429-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T09:02:26Z","timestamp":1750410146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-025-01429-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1007\/s11910-025-01429-3","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"12 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"42"}}